Apalutamide (Erleada™)


Indications for Prior Authorization:

  • Treatment of patients with non-metastatic castration-resistant prostate cancer (NM-CRPC)

Patients must meet the following criteria for the indication(s) above:

  • Diagnosis of non-metastatic, castration-resistant prostate cancer (NM-CRPC), AND
  • Prescribed by or in consultation with an oncologist or urologist, AND
  • Patient will receive a gonadotropin-releasing hormone (GnRH) analog concurrently or has had bilateral orchiectomy


  • 240 mg (four 60mg tablets) once daily
  • Bone support should be used in patients receiving Erleada


  • 1 year

Last review date: April 23, 2019

WHA is closely monitoring the Coronavirus Disease 2019 (COVID-19). Learn more about COVID-19.